Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.

Date publication

mai 2014

Journal

Annales pharmaceutiques francaises

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis , Dr FAGNONI Philippe , Dr GUIGNARD Marie-Hélène , Dr SGRO Catherine , Dr CHRETIEN Marie-Lorraine

Tous les auteurs :
Monnier A, Malbranche C, Fagnoni P, Serge Aho L, Guerard P, Sgro C, Guignard MH, Croisier-Bertin D, Chavanet P, Chrétien ML, Caillot D, Boulin M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24780833

Résumé

Concerns have recently emerged about the quality of generic vancomycin products. Our aim is to analyze serum vancomycin concentrations measured 48 hours after the start of an empirical treatment regimen in patients with acute myeloid leukemia (AML) who received one of the two generic vancomycin products available in France.

Mots clés

Adolescent, Adult, Aged, Anti-Bacterial Agents, blood, Drugs, Generic, Female, Humans, Kidney, metabolism, Leukemia, Myeloid, Acute, metabolism, Male, Middle Aged, Retrospective Studies, Vancomycin, blood, Young Adult

Référence

Ann Pharm Fr. 2014 May;72(3):178-83